Journal of Enzyme Inhibition and Medicinal Chemistry · 2016 · 23 citations · 40 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryNeuropharmacologyStructure-activity RelationshipsAntidepressant PharmacologyAntidepressant PharmacotherapyDrug-receptor InteractionsLigand BindingReceptor PharmacologySerotonergic PharmacologyAntidepressant EfficacyAntidepressant MedicationsAntidepressant ResponseInhibitor ScreeningLigand-receptor AffinityPharmacodynamic MechanismsReceptor Binding OptimizationSerotonin Receptor Pharmacology
receptor ligands with weak inhibitory potencies for PDE4B and PDE10A. The tests have been completed with the determination of lipophilicity and metabolic stability using micellar electrokinetic chromatography (MEKC) system and human liver microsomes (HLM) model. In preliminary pharmacological in vivo studies, selected compound 8-(5-(4-(2-fluorophenyl)piperazin-1-yl)pentyl)-1,3,7-trimethyl-1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione (9) behaved as a potential antidepressant in forced swim test (FST) in mice. Moreover, potency of antianxiety effects evoked by 9 (2.5 mg/kg) is greater than that of the reference anxiolytic drug, diazepam. Molecular modeling revealed that fluorinated arylpiperazinylalkyl derivatives of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione have major significance for the provision of lead compounds for antidepressant and/or anxiolytic application.
40
SWISS-MODEL: an automated protein homology-modeling server
Torsten Schwede · Nucleic Acids Research · 2003 · 5.7K citations · Full text
Lipophilicity in drug discovery
Michael J. Waring · Expert Opinion on Drug Discovery · 2010 · 844 citations